Modern CNS Drug Discovery
Springer International Publishing (Verlag)
978-3-031-61991-5 (ISBN)
- Noch nicht erschienen - erscheint am 31.01.2025
- Versandkostenfrei
- Auch auf Rechnung
- Artikel merken
This new edition is a comprehensive guide to the intricate world of drug discovery and development. It provides readers with an update on basic and novel concepts, approaches and technologies that are used in the discovery and development of new therapeutics for diseases of the central nervous system (CNS). A major aim is to support the education of professionals and specialists in the biomedical neurosciences that will become the innovators, entrepreneurs, and leaders of the future. The educational focus is now enhanced by the inclusion of over 150 study questions available in the free Springer Nature Flashcard App, which makes this a unique book in its field.
Divided into five sections, the book starts by introducing concepts and ideas to inspire the next generation of life scientists pursuing careers in drug discovery for CNS diseases. In the following section, key strategies and methods for identifying and testing novel drug targets are described. New chapters on important topics have been added, that is, the blood brain barrier, mass spectrometry, biased signaling and the exposome. The third section highlights strategies and technologies in translational CNS drug discovery and looks at safety and drug metabolism assessment, imaging techniques and functional testing to investigate drug treatment outcomes. The chapters in the fourth section address the emergence of transdiagnostic approaches as exemplified by the Research Domain Criteria initiative and non-invasive brain stimulation techniques. Finally, the book concludes with the late stages of drug development, such as the planning and performance of clinical trials, and regulatory approval.
Written by experts from academia and industry, the book covers important fundamentals and best practices as well as current developments in neurotherapeutic research. It offers in-depth insights into the world of drug development and is essential reading for young scientists who are interested in translational research and want to prepare for an academic or industry career in CNS drug discovery.
Rudy Schreiber got his B.S. in Medicinal Biology and his Ph.D. in Neuropharmacology from the University of Groningen in the Netherlands. He started his career in central nervous system drug discovery in 1993. Subsequently he progressed from bench scientist to senior leadership roles at global pharmaceutical companies, including Servier (France), Bayer (Germany), Roche (CA) and Sepracor (currently, Sumitomo Pharma America, Inc, MA). From 2010 till 2012 he was the SVP of the Neurobiology group of the contract research organization, Evotec (Germany). Rudy's drug discovery experience covers a wide range of psychiatric and neurologic indications. He also worked with many different classes of molecular targets and led projects ranging from the idea stage throughout proof of principle testing. He has published more than 100papers and 30 patents. In 2012, he founded Suadeo Drug Discovery Consulting LLC in Boston. Rudy joined Maastricht University in 2018 and is coordinator of the 2-year research master program Drug Development and NeuroHealth. After this career change, he (re)discovered his interest for education, especially for training the next generation of drug hunters and neuro-entrepreneurs. Modern CNS Drug Discovery is a testament to this new found passion. Rudy is a Homo Aquaticus who lives on a boat in Maastricht Marina and spends his free time rowing on the Maas River or sailing offshore.
Part 1. Training the next generation of life science professionals.-Chapter 1. Preparing drug discovery scientists for a career in start-ups.-Chapter 2. Innovator, Entrepreneur, Leader: The Tripartite Drug, Discovery Neuroscientist.- Chapter 3. From Scientists to Innovators for Industry: an European program addressing the workforce challenge in the pharma industry.-Part 2. Recent developments in CNS drug discovery: from genes and molecules to animals.-Chapter 4. Drug Discovery in CNS: Finding a Target for What?.-Chapter 5. The Guardian of the Brain: Understanding the Blood-Brain Barrier and its Role in CNS Drug Discovery.-Chapter 6.Mass Spectrometry-Based Methods in CNS Drug Discovery.-Chapter 7. Neurogenomics with Application to Schizophrenia and Other Major Neuropsychiatric Diseases with Complex Heredity.-Chapter 8. Epigenetics in Drug Discovery: Achievements and Challenges.-Chapter 9.CNS biased agonism and the promise of targeting drugs beyond receptors to cellular pathways.-Chapter 10. Conventional Behavioral Models and Readouts in Drug Discovery: The Importance of Improving Translation.-Part 3. Translational Neuroscience and Technology.-Chapter 11. Connecting the dots in translational neuroscience.-Chapter 12. Safety and Drug Metabolism: Toward NCE and First in Human.-Chapter 13. Electrophysiology: From Molecule to Cognition, from Animal to Human.-Chapter 14. MRI in CNS Drug Development.-Chapter 15. Positron Emission Tomography in Drug Development.-Chapter 16. Application of Cognitive Test Outcomes for Clinical Drug Development.-Chapter 17. Exciting Research in the Field of Sexual Psychopharmacology: Treating Patients with Inside Information.-Part 4. Transdiagnostic Neurotherapeutics.-Chapter 18. Transformative CNS drug discovery.-Chapter 19.A Paradigm Shift from DSM-5 to Research Domain Criteria: Application to Translational CNS Drug Development.-Chapter 20.The exposome paradigm: applications in psychopathology and psychopharmacology.-Chapter 21. Medical devices for neurmodulation: A Comprehensive Overview of Different Methods of Non-invasive Brain Stimulation.-Chapter 22. Non-invasive Brain Stimulation: an evidence-based nonpharmacological treatment for Psychiatric and Neurological disorders.-Part 5. Clinical Development and regulatory approval.-Chapter 23.The Special Challenges of Developing CNS Drugs.-Chapter 24_Phase 1 Clinical Trials in Psychopharmacology.-Chapter 25. Early Development of Erenumab for Migraine Prophylaxis.-Chapter 26. Microdosing Psychedelics as a Promising New Pharmacotherapeutic.-Chapter 27.Partnering with the FDA.
| Erscheint lt. Verlag | 31.1.2025 |
|---|---|
| Zusatzinfo | XIX, 447 p. 80 illus., 63 illus. in color. |
| Verlagsort | Cham |
| Sprache | englisch |
| Maße | 178 x 254 mm |
| Themenwelt | Medizin / Pharmazie ► Medizinische Fachgebiete ► Pharmakologie / Pharmakotherapie |
| Medizin / Pharmazie ► Pharmazie | |
| Medizin / Pharmazie ► Studium | |
| Naturwissenschaften ► Biologie ► Humanbiologie | |
| Schlagworte | Biomarkers • brain imaging • central nervous system • clinical development • clinical trial • drug development • drug discovery • drug pipeline • Drug Screening • FDA • medicinal chemistry • model systems • Neuroinformatics • Neurological disorders • Novel therapeutics • Pharmacokinetics • psychiatric disorders • Psychopharmacology • regulatory approval • Toxicology |
| ISBN-10 | 3-031-61991-9 / 3031619919 |
| ISBN-13 | 978-3-031-61991-5 / 9783031619915 |
| Zustand | Neuware |
| Informationen gemäß Produktsicherheitsverordnung (GPSR) | |
| Haben Sie eine Frage zum Produkt? |
aus dem Bereich
